PubMed Health⌕ Search

Biomedical subjects

Ivan Berlin

Publications and source records attributed to Ivan Berlin.

At least 19 recordsLinked to original sources
PubMed2006

Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits.

AIMS: To examine whether mood, personality and coping predict smoking cessation and whether the associations of personality and coping are mediated through depressed mood. SETTING: Multicenter (n = 8) smoking cessation trial. PARTICIPANTS: A total of 600 smokers (> or = 15 cigarettes/day) without current depression who participated in a smoking cessation study. MEASUREMENTS: The outcome was continuous abstinence during the last 4 weeks of the 3-month trial: depressed mood was measured by the Beck Depression Inventory (BDI), personality by the Revised NEO Personality Inventory (NEO-PI-R) and coping by the Revised Ways of Coping Checklist (RWCC). FINDINGS: A total of 14.7% (88/600) were abstainers. Controlling for potential confounders, baseline BDI independently predicted smoking cessation. Smokers with BDI > or = 10 were less likely to quit than those with BDI < 10 (odds ratio: 6.39, 95% CI: 1.44-28.3, P = 0.01). Compared to BDI < 10 smokers, BDI > or = 10 smokers had significantly higher scores for neuroticism and lower scores for extraversion and conscientiousness (NEO-PI-R). On the RWCC, BDI > or = 10 smokers scored higher for blame self, wishful thinking and problem avoidance and they scored lower on problem focus than smokers with BDI < 10. A mediational analysis showed that neither personality traits nor coping skills predicted directly smoking cessation. However, low level of problem focusing and social support seeking predicted a negative outcome via depressed mood. CONCLUSION: A BDI score > or = 10, even in smokers who do not meet a current diagnosis of major depression, directly predicts inability to quit. This suggests the utility of assessing depression symptoms in routine smoking cessation care.

Adaptation, Physiological↗
PubMed2005

Expired air carbon monoxide concentration in mothers and their spouses above 5 ppm is associated with decreased fetal growth.

BACKGROUND: Smoking during pregnancy is associated with reduced birthweight; this relation can be reversed by smoking cessation. Some but not all previous studies have shown that smoking reduction (measured as cigarettes/day or urinary cotinine) may also improve birthweight. The relationship between maternal and spouses' expired air carbon monoxide (CO) concentrations (EACO) on fetal growth has not yet been evaluated. METHODS: Eight hundred fifty-six smoking and nonsmoking pregnant women were followed during their pregnancy. Their EACO was determined in the first trimester and during delivery. The spouses' EACO were also measured at delivery. The main outcome measure was the infants' birthweight. Secondary measures included head circumference, Apgar score, and heart rate at delivery. Cord blood fetal carboxyhemoglobin (FCOHb) served as internal control. RESULTS: Birthweight dose-dependently and significantly decreased with increasing level of maternal (0-5: 3406 +/- 32; 6-10: 3048 +/- 57; 11-20: 2858 +/- 54; >20 ppm: 2739 +/- 34 g, P < 0.0001) or spouses' EACO (0-5: 3546 +/-25; 6-10: 3484 +/- 51; 11-20: 3309 +/- 47; >20 ppm: 3190 +/- 57 g, P < 0.0001). Even the birthweight of newborns whose mother had EACO between 6 and 10 ppm was significantly lower than the birthweight of newborns whose mother had an EACO between 0 and 5 ppm. Spouses' EACO of delivering women with EACO of 0-5 ppm showed similar effect. Head circumference, Apgar score, and normal term gestational age decreased also significantly with increasing maternal or spouses' EACO. CONCLUSIONS: Both maternal and spouses' EACO measured during delivery, a proxy of EACO during pregnancy, were dose-dependently and inversely associated with fetal growth. Even low maternal (6 to 10 ppm) or spouses' (11 to 20 ppm) EACO may be associated with significantly lower birthweight.

Adolescent↗
PubMed2005

Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation.

One previous report (Cinciripini et al., [2004] Nicotine & Tobacco Research, 6, 229-239) found that the D2 dopamine receptor (DRD2) TaqI A polymorphism was associated with smoking cessation: Carriers of the A1 allele were less likely to quit than were those who were not carriers. If confirmed, this finding would allow one to use precessation genotyping to predict the likelihood of successful quitting. The present study reports on results of a similar smoking cessation study and uses the same methods and data analysis in a larger number of smokers. It fails to replicate the effect of DRD2 TaqI A polymorphism on smoking cessation.

Adult↗
PubMed2005

Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach.

AIMS: To describe the effect of nicotine replacement therapy (NRT) on the risk of relapse as a function of time since the quit date. DATA SOURCES: Meta-analysis of 21 published, randomized, controlled clinical trials, comparing NRT to placebo. DATA EXTRACTION: A total of 6644 smokers were treated with NRT and 2766 smokers treated with placebo. DATA SYNTHESIS: During treatment with the medication, NRT reduced the hazard ratio (HR) significantly compared with placebo [early HR = 0.62 (95% CI: 0.58-0.67)]. At the end of the average treatment duration (145 days), the HR was 0.81 (95% CI: 0.71-0.94), showing that the benefit was still present at this time. After stopping treatment, the HR increased progressively up to a value of 1.44 (95% CI, 1.18-1.76) showing that the risk of relapse was higher after stopping NRT than after stopping placebo. If NRT and placebo had not been stopped, the HR of smoking relapse would have been established at 0.95 (95% CI: 0.76-1.18, P = 0.64), indicating a similar risk of relapse with NRT and placebo. Moreover, the observed HR of smoking relapse was significantly higher than the expected HR of smoking relapse if NRT had been continued: the difference in HR is 1.51 (95% CI: 1.16-1.98, P < 0.003). This suggests that if NRT had been been continued, around 50% of relapses could have been prevented. CONCLUSION: The protective effect of NRT against relapse slowly decreases as a function of time. After stopping NRT, the risk of relapse increases. It may be more beneficial not to stop NRT after the usual 3-6-month treatment period but to use NRT for longer periods of time.

Adult↗
PubMed2005

Reliability and validity of the French version of the tobacco craving questionnaire.

OBJECTIVES: (1) To assess the factorial structure, reliability and validity of the French language version of the Tobacco Craving Questionnaire (TCQ), a multidimensional, self-report instrument evaluating tobacco craving, to allow its use in French-speaking populations. (2) To compare the two different language versions of the same instrument in 2 independent samples from 2 cultures in 2 distinct time periods. METHODS: The French TCQ was administered to 226 current cigarette smokers after at least 2 h of abstinence. RESULTS: Despite the substantial difference in population characteristics between the French and American samples of smokers, both exploratory and confirmatory factor analyses indicated that the French version was best described by a 4-factor solution, similar to the original English version. Reliability estimates were 0.83, 0.79, 0.69 and 0.66 for the French and 0.82, 0.70, 0.75 and 0.48 for the English version for 'emotionality' (factor 1), 'expectancy' (factor 2), 'compulsivity' (factor 3) and 'purposefulness' (factor 4), respectively. The 4 factors accounted for 11.6, 17.1, 9.0, and 9.5% of the total variance in emotionality, expectancy, compulsivity, and purposefulness, respectively, for the French compared to 14.2, 12.5, 14.4 and 5% of the total variance for the English version, respectively. CONCLUSION: The French version of the TCQ is as valid and reliable instrument as the original English version and assesses the same 4 dimensions of craving for tobacco.

Adult↗
PubMed2004

[Current therapeutic strategies in smoking cessation].

Smoking is a behaviour maintained and enhanced by a dependence mainly induced by nicotine. Despite awareness and knowledge of the associated health risks many smokers find it considerably difficult to quit. The untoward effects of nicotine withdrawal such as apparition of depressive mood, or weight gain, etc. justify the numerous unsuccessful attempts to quit smoking. Treatments with demonstrated efficacy are available and international evidence-based recommendations for cessation interventions have been established. These are: brief advice, assessing the smoking status of each patient and encouraging cessation; nicotine replacement therapies (NRT) [transdermal patch, gum, sublingual tablet or inhalator to be used at sufficiently individualised doses combining, if necessary, two or more NRT products]; bupropion, a more recent treatment: psychotropic drug, a noradrenaline and dopamine re-uptake inhibitor more recently approved for marketing; behavioural and cognitive therapies on their own or combined with pharmacotherapy. Measuring nicotine dependence using the Fagerström Test for Nicotine Dependence may help to define the therapeutic strategy. It is obvious that therapies can only work for smokers who are motivated to stop smoking. Before reaching the decision to quit, the smoker goes through a process in the course of which the role of health professionals' advice is paramount.

Administration, Cutaneous↗
PubMed2004

Effect of glucose on tobacco craving. Is it mediated by tryptophan and serotonin?

RATIONALE: Oral glucose has been shown to decrease tobacco craving in many but not all previous studies. Glucose ingestion may facilitates entry of tryptophan (TRP), the unique source of brain serotonin, into the brain, glucose's action seems to be opposite of rapid TRP depletion. Therefore, the aim was to assess the effect of high doses of oral glucose on tobacco craving, withdrawal symptoms, plasma TRP and blood serotonin concentrations in temporarily abstinent smokers. METHODS: Aspartame 0.6 g/200 ml (A, placebo), glucose 32.5 g/200 ml (G32.5) and 75 g/200 ml water (G75) were administered to 12 healthy smokers after an overnight abstinence in a crossover, double blind study. Tobacco craving (short version of the Tobacco Craving Questionnaire, TCQ), withdrawal symptoms, choice reaction time, affect, blood glucose, plasma insulin, nicotine, cotinine, free and total TRP, and blood serotonin concentrations were assessed during a period of 5 h after administration. RESULTS: Blood glucose and plasma insulin increased after G32.5, G75 and remained unchanged after A. TCQ score increased with A and remained almost unchanged with both doses of glucose (conditionxtime interaction: P=0.023). Total withdrawal score increased differently according to sex and condition (P<0.05). Motor reaction time increased with A and decreased with glucose (P=0.016). The overall decrease in plasma TRP was 0.31+/-17, 0.49+/-0.19 and 1.44+/-0.24 mg/l with A, G32.5 and G75, respectively (P<0.001). Baseline blood serotonin was lower in women (n=5) than in men; it showed a condition by time (P=0.007) and a condition by time by sex interaction (P=0.023). CONCLUSIONS: Glucose attenuates tobacco craving and withdrawal symptoms in temporarily abstinent smokers. This is accompanied by a decrease in plasma TRP and a sex dependent increase in blood serotonin. Further studies assessing the direct effect of glucose on brain serotonin are needed to ascertain whether a glucose induced reduction in craving is associated with an increase in brain serotonin.

Administration, Oral↗
PubMed2004

Impulsivity in smoking, nonsmoking, and ex-smoking alcoholics.

The impulsivity levels were evaluated and compared in smoking, nonsmoking, and ex-smoking abstinent alcoholics (N=400) in a French alcohol detoxification center. Impulsivity was measured using the Barratt Impulsiveness Scale, French version (BIS 10). The BIS scores correlated inversely with age. Gender had no effect on impulsivity scores, while impulsivity was associated with smoking. Adding age as a covariate, however, eliminated or moderated the association, with three exceptions: (1) among males, heavy smokers were more impulsive than nonsmokers and medium smokers; (2) on the nonplanning subscale, heavy smokers were more impulsive than all other groups, and (3) current smokers were more impulsive than ex-smokers. Elevated impulsivity levels appear to be an obstacle to smoking cessation. In addition, stopping smoking may diminish impulsivity levels in alcoholics. Routine testing of impulsivity in current alcoholic smokers might predict who might successfully become an ex-smoker.

Adolescent↗
PubMed2004

Tobacco smoking trajectory and associated ethnic differences among adolescent smokers seeking cessation treatment.

PURPOSE: To examine smoking trajectories in a clinical sample of adolescent smokers seeking cessation treatment, including: (a) smoking onset (initial, daily) and time intervals from initial to daily smoking and from daily smoking to treatment request, (b) associations between current level of tobacco dependence and smoking history, and (c) differences in smoking trajectory between African-American and non-African-American youth. METHODS: Four hundred and thirty-two adolescent smokers (aged 13-17 years, 61.8% female, 32% African-American) responding to various media advertisement completed a telephone interview as part of pre-eligibility screening for a smoking cessation trial. Smoking trajectory data included age at onset of initial and daily smoking, intervals between those time points, and cigarettes smoked per day (CPD). Tobacco dependence was assessed using the Fagerström Test for Nicotine Dependence (FTND). Data were analyzed using regression models and multiple analyses of covariance. RESULTS: Initial smoking occurred at a mean age of less than 12 years and daily smoking at age 13 years. Earlier onset of daily smoking was associated with higher FTND scores and longer duration from daily smoking to treatment request. For the entire sample, the time interval from initial to daily smoking was 1.14 years. When the sample was divided into early (before age 14 years) and later (at or after age 14 years) initiators, early initiators showed a slower progression from initial to daily smoking compared with late initiators (16 months vs. 6 months). Compared with non-African-American teen smokers, African-American youth reported a 1-year delay in onset of both initial and daily smoking. CONCLUSIONS: Early age of daily smoking and short time interval from initial to daily smoking highlight a brief window of opportunity to prevent the development of tobacco addiction and its consequences. Ethnic differences in smoking trajectory uncovered in this report call for ethnically tailored interventions to reduce youth smoking.

Adolescent↗
PubMed2004

Should major depression with 'high normal' thyroid-stimulating hormone be treated preferentially with tricyclics?

In a prospective and naturalistic setting, two samples representing 209 depressed inpatients were assessed for thyroid functioning at admission before antidepressant treatment, and for depression before and after 1 month of antidepressant treatment. We hypothesized that serum thyroid-stimulating hormone (TSH) elevation > or = upper 25th percentile of the normal reference range is associated with poorer response to antidepressant therapy and differences between tricyclic antidepressants (TCA) and other antidepressants. Screening for mild thyroid failure defined as serum TSH concentrations > or = upper 25th percentile of the normal range may provide clues to the clinician. Such patients have a more severe form of depression and a slower or impaired response to antidepressant therapy. It is also possible that they would benefit preferentially from TCA rather than other antidepressants.

Adolescent↗
PubMed2003

Characteristics of African American teenage smokers who request cessation treatment: implications for addressing health disparities.

BACKGROUND: Ethnoracial disparities in both tobacco-related mortality and treatment outcome for smoking cessation have been reported among adults, but there is a dearth of information on ethnoracial differences among adolescent smokers. OBJECTIVE: To compare smoking-related characteristics in African American and non-African American teenaged applicants for a smoking cessation trial. PARTICIPANTS, DESIGN, AND SETTING: Four hundred thirty-two teenaged smokers (mean [SD] age, 15.6 [1.5] years; 61.8%, female; 31.9%, African American) responded via telephone to various media advertisements. Self-reported sociodemographic, smoking-related, and clinical data were obtained to determine preeligibility for trial participation. MAIN OUTCOME MEASURES: The number of cigarettes smoked per day, Fagerström Test for Nicotine Dependence (FTND) score, motivation to quit, self-reported health problems, and medication use. RESULTS: Compared with non-African Americans, African Americans had lower FTND scores (mean [SD] score, 5.31 [2.24] vs 6.18 [2.18]; P<.01), and smoked fewer cigarettes per day (mean [SD] number of cigarettes, 12.6 [8.3] vs 15.4 [7.5] cigarettes/d; P<.04). The FTND scores were similar in both groups when adjusted for the number of cigarettes smoked per day. African American and non-African American teenagers reported similar motivation to quit (mean [SD] score, 8.64 [1.68] vs 8.53 [1.59], respectively). No difference was found in frequency of physical health problems (eg, asthma), diagnosed psychiatric conditions, or prescribed psychiatric medication although fewer African American teenaged smokers took medication for physical problems (21.2% vs 36.7%). CONCLUSIONS: Cessation treatment interventions designed for African American youths should include lower FTND-defined levels, or the use of other instruments that do not focus on the number of cigarettes smoked per day. Our findings also highlight the importance of ethnocultural issues in treatment research that aims to address health disparities.

Adolescent↗
PubMed2003

Relationship between body-mass index and depressive symptoms in patients with major depression.

BACKGROUND: Appetite and weight changes are commonly occurring symptoms of depressive illness. The occurrence of these symptoms may not only be related to depressive mood but may also be related to body weight. AIM: To examine the relationship between symptoms of depression and body weight. METHODS: Symptoms of depression were assessed by the Montgomery-Asberg depression rating scale (MADRS) in 1694 patients seeking medical help and fulfilling DSM-IV criteria for a major depressive episode. The level of anxiety was evaluated by Covi's anxiety scale. Body weight was expressed as body-mass index (BMI, kg/m(2)) and treated both categorically and continuously. RESULTS: The total MADRS score was not statistically different across the four BMI categories (underweight: 32.3 +/- 0.6, normal weight: 30.9 +/- 0.2, grade 1: 30.6 +/- 0.3, and 2 overweight: 30.6 +/- 0.6, P = 0.053 (NS)). In women with BMI <or= 18.5 kg/m(2) MADRS was significantly higher than that in other BMI categories (underweight: 32.4 +/- 0.6, normal weight: 30.6 +/- 0.2, grade 1: 30.6 +/- 0.4, and 2 overweight: 30.6 +/- 0.6: P = 0.036). Increasing BMI was related to a linear decrease in symptoms "Reduced appetite" (P < 0.0001) and "Pessimistic thoughts" (P < 0.003). The presence of melancholic or atypical features was not associated with lower or higher BMI, respectively. CONCLUSIONS: In patients with major depression higher body weight is likely to be associated with less reduction in appetite and less pessimistic thoughts.

Adult↗
PubMed2003

The Modified Reasons for Smoking Scale: factorial structure, gender effects and relationship with nicotine dependence and smoking cessation in French smokers.

AIMS: To assess the validity of the French version of the Modified Reasons for Smoking Scale (MRSS), and to identify which smoking patterns differentiate male and female smokers, which are related to tobacco dependence (as assessed by the Fagerström Test for Nicotine Dependence, FTND), to mood (Beck Depression Inventory II), to affect (Positive and Negative Affect Schedule) and which are predictors of successful quitting. PARTICIPANTS: Three hundred and thirty smokers [(mean +/- SD) aged 40 +/- 9 years, 145 (44%) women, mean FTND score: 6.2 +/- 2], candidates for a smoking cessation programme and smoking at least 15 cigarettes/day. FINDINGS: Factor analysis of the 21-item scale gave the optimal fit for a seven-factor model, which accounted for 62.3% of the total variance. The following factors were identified: 'addictive smoking', 'pleasure from smoking', 'tension reduction/relaxation', 'social smoking', 'stimulation', 'habit/automatism' and 'handling'. The 'addictive smoking' score increased in a dose-dependent manner with number of cigarettes smoked per day; the 'habit/automatism' score was significantly higher, with more than 20 cigarettes per day than with < or = 20 cigarettes per day. The reasons for smoking were different for males and females: females scored higher on 'tension reduction/relaxation', 'stimulation' and 'social smoking'. A high level of dependence (FTND > or = 6) was associated with significantly higher scores only on 'addictive smoking', the association being stronger in females. Time to first cigarette after awakening was associated with higher 'addictive smoking' and 'habit/automatism' (P < 0.001). In a multivariate logistic regression, failed quitting was predicted by higher habit/automatism score (odds ratio = 1.44, 95% CI = 1.06-1.95, P = 0.02) and greater number of cigarettes smoked per day (odds ratio = 1.03, 95% CI = 1.01-1.06, p = 0.03). CONCLUSIONS: The questionnaire yielded a coherent factor structure; women smoked more for tension reduction/relaxation, stimulation and for social reasons than men; addictive smoking and automatic smoking behaviour were similar in both sexes and were associated strongly with a high level of nicotine dependence; the 'habit/automatism' score predicted failure to quit over and above cigarettes per day.

Adolescent↗
PubMed2003

Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.

Apomorphine (APO) stimulates growth hormone (GH) release via dopamine D2 receptors (DRD2). There is no specific study assessing the relationship between APO pharmacokinetic (PK) and the pharmacodynamic (PD) response e.g. GH release. The objective of the study is the PK-PD modelling of APO in healthy subjects. This is a randomized crossover study with s.c. administration of 5, 10, and 20 micro g/kg of APO in 18 healthy subjects. APO concentrations were modelled according to both a bi-compartmental model with zero-order absorption and a bi-compartmental model with first-order absorption. PK-PD relationship was modelled in accordance with the Emax Hill equation using plasma concentrations of APO calculated according to the bi-compartmental model with zero-order absorption. Modelled parameters were very similar to the experimental parameters. PK of APO was linear and there was no significant difference between the tested doses for AUC0--> infinity and Cmax (normalised to the dose 1 micro g/kg), t1/2alpha and t1/2beta. These parameters expressed as mean (CV%: SD/mean) were: 17.2 (26.9) ng/mL.min, 0.26 (33.3) ng/mL, 17.1 (54.2) and 45.2 (20.6) min, respectively (n = 53). An anticlockwise hysteresis loop (effect function of APO plasma concentration) appeared for each dose and each subject. The predicted and measured GH concentrations for all subjects and times were similar whatever the dose (P > 0.27). Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4). APO and GH concentrations were predicted with good accuracy using bi-compartmental with zero-order absorption PK model and sigmoid Emax PD model, respectively.

Adult↗
PubMed2002

Hedonic response to sucrose solutions and the fear of weight gain in patients with eating disorders.

Previous research has shown that patients with bulimia nervosa (B), anorexia nervosa, restricting type, or restrictive-anorectic (RA), and anorexia nervosa, binge eating, purging type, or anorectic-bulimic (AB) exhibit a reduced hedonic response to sucrose compared with control subjects. We hypothesized that this response could be linked to an excessive fear of weight gain rather than a decreased ability to experience pleasure. We therefore compared the hedonic responses to sucrose solutions in B, RA and AB women (n=20/group) in two different conditions: sucrose solution swallowed vs. sucrose solution spit. Under double-blind conditions and according to a Latin square design, patients received sucrose in solution (0, 5, 10, 20, and 40%) and rated each concentration for pleasantness on a nine-point scale. The two test conditions were randomly administered. The threshold concentration of sweet taste perception was also assessed, and the subjects filled out Chapman's Social and Physical Anhedonia Scale. The hedonic response to sucrose adjusted for the sweet taste perception threshold was significantly lower in the 'swallow' than in the 'spit' condition. There was a significant effect of sucrose concentrations as well as a significant condition by concentration interaction. When 'fear to swallow' sucrose solution responses were included as a covariate, the significant difference between the conditions of 'swallow' or 'spit' disappeared, but there was a significant concentration by condition by fear to swallow interaction and an almost significant covariate effect. When 'Drive for Thinness' on the Eating Disorder Inventory was included as a covariate, similar results were obtained. Social Anhedonia but not Physical Anhedonia correlated positively with 'Drive for Thinness' and 'fear of swallowing sucrose solutions', and correlated inversely with maximal hedonic response to the 'swallow' condition. 'We conclude that the hedonic responses to sucrose in patients with eating disorders are decreased when solutions are swallowed. This may reflect excessive fear of gaining weight rather than decreased ability to experience pleasure'.

Administration, Oral↗
PubMed2002

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.

BACKGROUND: Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's addictive potential. AIMS: To assess whether lazabemide, a reversible selective MAOB inhibitor, promotes smoking cessation. STUDY DESIGN: Double-blind, randomized, placebo-controlled, multicenter phase II study. Placebo, lazabemide 100 mg/day and 200 mg/day were administered for 8 weeks. This was a dose finding, proof-of-concept, exploratory study. SETTING: General practices and anti-smoking clinics in France and Belgium. PARTICIPANTS: Smokers smoking > or=15 cigarettes per day and motivated to quit. MAIN OUTCOME MEASURE: Sustained abstinence during the last 4 weeks of the study. FINDINGS: The study was discontinued prematurely by the sponsor before randomization of the planned 420 smokers because of liver toxicity observed in other indications. Data of 330 randomized subjects could be analysed. Sustained abstinence during the last 4 weeks of treatment was 9%, 11% and 17% in the intent-to-treat population [P for trend: 0.036 (one-sided)]; 11%, 14% and 21% in the intent-to-treat population of smokers without those excluded because of discontinuation of the study [n = 262, P for trend: 0.02 (one-sided)], and 19%, 27% and 35% in completers [P for trend: 0.03 (one-sided)], in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively. Point prevalence abstinence (intent-to-treat population) at the end of treatment (week 8) was 17%, 19% and 30% in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively (placebo vs. lazabemide 200 mg/day: P = 0.01, one-sided). No treatment emergent major adverse event occurred. More nausea and insomnia were reported with lazabemide than with placebo. CONCLUSIONS: MAOB inhibitors are promising treatments as an aid in smoking cessation. There may be an interest to develop MAOB inhibitors with an acceptable toxicity profile. Further studies may associate MAOB inhibitors with nicotine replacement therapies to increase therapeutic efficacy.

Adult↗